Email updates

Keep up to date with the latest news and content from BMC Microbiology and BioMed Central.

Open Access Highly Accessed Research article

Enterohepatic bacterial infections dysregulate the FGF15-FGFR4 endocrine axis

Guillaume Romain1, Sarah Tremblay1, Ellen T Arena25, L Caetano M Antunes26, Scott Covey3, Michael T Chow47, B Brett Finlay23 and Alfredo Menendez1*

Author Affiliations

1 Department of Microbiology and Infectious Diseases, Faculty of Medicine and Health Sciences, University of Sherbrooke, Cancer Research Pavilion, Rm Z8-1072, 3201, rue Jean-Mignault, Sherbrooke, Québec J1E 4K8, Canada

2 Michael Smith Laboratories, The University of British Columbia, Vancouver, BC V6T 1Z4, Canada

3 Department of Biochemistry and Molecular Biology, The University of British Columbia, Vancouver, BC V6T 1Z3, Canada

4 Department of Microbiology and Immunology, University of British Columbia, Vancouver, BC V6T 1Z3, Canada

5 Present address: Unité de Pathogénie Microbienne Moléculaire Institut Pasteur, 28 rue du Dr Roux, F – 75724, Paris Cédex 15, France

6 Present address: Escola Nacional de Saúde Pública Sergio Arouca, Fundação Oswaldo Cruz, Rua Leopoldo Bulhões, 1480, Rio de Janeiro, RJ 21041-210, Brazil

7 Present address: Qu Biologics Inc, 887 Great Northern Way, Suite 138, Vancouver, BC V5T 4T5, Canada

For all author emails, please log on.

BMC Microbiology 2013, 13:238  doi:10.1186/1471-2180-13-238

Published: 29 October 2013

Abstract

Background

Enterohepatic bacterial infections have the potential to affect multiple physiological processes of the body. Fibroblast growth factor 15/19 (FGF15 in mice, FGF19 in humans) is a hormone that functions as a central regulator of glucose, lipid and bile acid metabolism. FGF15/19 is produced in the intestine and exert its actions on the liver by signaling through the FGFR4-βKlotho receptor complex. Here, we examined the in vivo effects of enterohepatic bacterial infection over the FGF15 endocrine axis.

Results

Infection triggered significant reductions in the intestinal expression of Fgf15 and its hepatic receptor components (Fgfr4 and Klb (βKlotho)). Infection also resulted in alterations of the expression pattern of genes involved in hepatobiliary function, marked reduction in gallbladder bile volumes and accumulation of hepatic cholesterol and triglycerides. The decrease in ileal Fgf15 expression was associated with liver bacterial colonization and hepatobiliary pathophysiology rather than with direct intestinal bacterial pathogenesis.

Conclusions

Bacterial pathogens of the enterohepatic system can disturb the homeostasis of the FGF15/19-FGFR4 endocrine axis. These results open up a possible link between FGF15/19-FGFR4 disruptions and the metabolic and nutritional disorders observed in infectious diseases.

Keywords:
Endocrine; Metabolism; Enterohepatic; Infection; FGF15; FGF19; FGFR4; βKlotho; Salmonella; Listeria